## AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions and listings of claims in this application.

## 1-19 (Canceled)

- 20. (Currently Amended) A method for treating patients a patient suffering from depression who have has a sleep disturbances disturbance when treated with a selective serotonin reuptake inhibitor other than escitalopram without inducing a sleep disturbance disturbances comprising administering a daily pharmaceutically effective amount of escitalopram or a pharmaceutically acceptable salt thereof to the patient, wherein the daily dose is 2.5 to 10 mg er-less of escitalopram or a pharmaceutically acceptable salt thereof.
- (Canceled)
- (Previously Presented) The method of claim 20, wherein the daily dose is 7.5 mg or less of escitalogram or a pharmaceutically acceptable salt thereof.
- 23. (Previously Presented) The method of claim 22, wherein the daily dose is 7.5 mg.
- 24. (Previously Presented) The method of claim 22, wherein the daily dose is 5 mg.
- (Previously Presented) The method of claim 20, wherein the pharmaceutically acceptable salt is an oxalate salt.
- 26. (Canceled)
- (Previously Presented) The method of claim 22, wherein the pharmaceutically acceptable salt is an oxalate salt

- (Previously Presented) The method of claim 23, wherein the pharmaceutically acceptable salt is an oxalate salt.
- (Previously Presented) The method of claim 24, wherein the pharmaceutically acceptable salt is an oxalate salt.
- (Previously Presented) The method of claim 25, wherein the pharmaceutically acceptable salt is a
  crystalline oxalate salt.
- 31. (Canceled)
- (Previously Presented) The method of claim 27, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.
- 33 (Previously Presented) The method of claim 28, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.
- (Previously Presented) The method of claim 29, wherein the pharmaceutically acceptable salt is a
  crystalline oxalate salt.